# Kiniksa Pharmaceuticals International plc Class A (KNSA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $77.91, market value $6.1 billion.

## Valuation
- **P/E (trailing): 78.7×** (5-yr avg 49.5×, 3-yr avg 71.4×). Kiniksa Pharmaceuticals International plc Class A trades at 78.7× trailing earnings, well above its own five-year average of 49.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 48.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.21**. A PEG of 0.21 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 7.2×**. Each dollar of revenue is priced at 7.2×.
- **Price / book: 9.3×**. The shares trade at 9.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 3.0%** (5-yr avg -1.6%). Free cash flow equals 3.0% of the market value, above its five-year average of -1.6%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 1.3%**. The inverse of the P/E: 1.3% of the price is earned each year.

## Profitability
- **Operating margin: 11.9%**. 11.9% of revenue is left after running the business.
- **Net margin: 8.7%**. 8.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.4%**. 10.4% on shareholders' equity is solid.
- **Return on assets: 10.6%**. Each dollar of assets produces 10.6% of profit.

## Growth
- **Revenue growth (1 yr): 60.1%** (3-yr 45.5%/yr). Revenue grew 60.1% over the last year.
- **EPS growth (1 yr): 225.0%** (3-yr -33.9%/yr). Earnings per share rose 225.0%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 188.1%/yr**. Free cash flow has compounded at 188.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Current ratio: 3.79** (quick 3.79). Current assets cover the next year's liabilities 3.79 times.
- **Altman Z-score: 21.48**. A Z-score of 21.48 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Kiniksa Pharmaceuticals International plc Class A does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 119.4%** (YTD 88.9%, 3-mo 60.9%). The shares are up 119.4% over twelve months including dividends.
- **From 52-week high: -6.1%** (121.3% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.24** (volatility 50%). Beta of 0.24 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KNSA · Page: https://foliofundamentals.com/stocks/knsa

Not investment advice.